Patients treated for hypertension are still at significantly elevated risk for cardiovascular complications when compared with normotensive patients, even when on antihypertensive therapy. In all fairness though, a majority of these patients have uncontrolled blood pressure. Blocking the renin-angiotensin-aldosterone system (RAAS) prevents or reverses cardiac remodelling and improves prognosis in cardiovascular disease beyond the effects on blood pressure (BP). Valsartan acts by selectively blocking the AT1-receptor and shows similar efficacy and improved tolerability compared with ACE inhibitors. This drug may provide additional benefits in controlling the cardiovascular complications of hypertension. Results of large clinical trials with valsartan, such as VALUE, Val-HEFT, VALIANT and ABCD-2V, are eagerly awaited.
1999 World Health Organisation-International Society of Hypertension Guidelines for the management of hypertension.J Hypertens1999; 17: 151–83.
2.
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.JAMA2000; 283: 1957–75.
3.
DahlöfB, HanssonL, LindholmLSTOP-Hypertension: Swedish Trial in Old Patients with Hypertension.J Hypertens1986; 4: 511–3.
4.
LeverAF, BeeversDG, HoleDJMortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why?Clin Exp Hypertens1999; 21: 553–62.
5.
YusufS, SleightP, PogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000; 342: 145–153.
6.
DahlöfB, Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.Blood Press Suppl1994; 2: 35–40.
7.
WingLM, ReidCM, RyanPSecond Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia.Clin Exp Hypertens1997; 19: 779–91.
8.
SchmiederRE, SchlaichMP.1998Comparison of therapeutic studies on regression of left ventricular hypertrophy.Adv Exp Med Biol1997; 432: 191–8.
9.
YalcinF, AksoyFG, Muderrisoglu H et al. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function.Clin Cardiol2000; 23: 437–41.
10.
KjeldsenSE, DahlofB, DevereuxRBLowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.Am J Hypertens2000; 8: 899–906.
11.
DevereuxRB, RomanMJ, PalmieriVLeft ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.J Hypertens2000; 8: 1129–38.
12.
ThurmannPA, KenediP, SchmidtA, HarderS, RietbrockN.Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.Circulation1998; 98: 2037–42.
13.
WachtellK, PalmieriV, OlsenMHParallel cardiac and renal end-organ damage in hypertensive patients with electro-cardiographic left ventricular hypertrophy.The LIFE Study. (Submitted).
14.
MuirheadN, FeaganBF, MahonJ.The effects of valsartan and capropril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial.Current Therapeutic Res2000; 60: 650–60.
15.
SchiffrinEL, ParkJB, IntenganHD, TouyzRM.Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.Circulation2000; 101: 1653–9.
16.
BlackHR, GraffA, ShuteDValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.J Hum Hypertens1997; 11: 483–9.
17.
CoreaL, CardoniO, FogariRValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.Clin Pharmacol Ther1996; 60: 341–6.
BodinF.Pharmacological and clinical profile of valsartan.J Hypertens2000; 18: S1–S7.
20.
MannJ, JuliusS.The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.Blood Pressure1998; 7: 176–83.
21.
CohnJN.Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.Cardiology1999; 91(Suppl 1): 19–22.
22.
PfefferMA, McMurrayJ, LeizoroviczAValsartan in acute myocardial infarction trial (VALIANT): rationale and design.Am Heart J2000; 140: 727–50.
